< View all reports

Bladder Cancer: Dynamic Market Forecast to 2026

Bladder cancer is a rapidly evolving field in which new developments are constantly influencing the market.

GlobalData’s Biosimilars market report consists of a slide deck specifying key market-impacting events that have occurred. It also includes an updated Excel-based forecasting model which reflects the expected influence of these events on the market in future.

  • Report Scope:
  • Timeline of market-impacting events
  • Key clinical trial landscape updates
  • New primary research to gain Key Opinion Leader perspective
  • Anticipated impact of events in the future
  • Forward-looking calendar listing expected updates to the Bladder Cancer competitive space through December 2018

Several events will drive change to the bladder cancer market landscape, including Spectrum Pharmaceuticals initiating Phase III CONQUER Trial for Apaziquone as adjuvant treatment in patients undergoing TURBT who have low-to-intermediate-risk NMIBC.

Despite being able to keep Tecentriq’s accelerated approval in this setting, Roche still needs to provide confirmatory data in order to receive full FDA approval. GlobalData expects Keytruda to overtake Tecentriq in the bladder cancer market.

Our Biosimilars market report will help you to stay well-informed on the latest news in the bladder cancer space, including regulatory, commercial, and clinical events. Use this report to gain an understanding of how all of these events will impact the projected market forecast.

Purchase Today

Single user $ 8,495

Buy Now

+44 (0) 161 359 5813

Not ready to buy yet? Download our free report series guide on the Biosimilars Market

I consent to GlobalData collecting my details provided via this form.

You are in control of the communications you receive from us and you can update your preferences anytime to make sure you are receiving information that matters to you. Please check our GlobalData Privacy Policy to see how we protect and manage your submitted data.